Novelogics Biotechnology, Inc. Unlike most treatments on the market that make cancer patients sick before they can get better, Novelogics' Interceptor approach focuses on safety to provide a better and more effective solution. With the potential to transform the direction of cancer treatment, Novelogics is attracting the attention of investors and pharmaceutical companies.

Their antibody immunotherapies for cancer are based on a novel concept that acts as an Interceptor of immunosuppressive proteins, which have the ability to shut down crucial cancer-fighting immune cells. By targeting this overlooked area in cancer biology, Novelogics aims to fill in the missing piece of the cancer puzzle. Led by Co-Founder Dr.

Wayne Cheney, who brings extensive experience in oncology research, Novelogics is driven by a team of experts dedicated to advancing cancer treatment. Novelogics is actively seeking staged investments and partnerships to further develop its program. With recent accolades for innovation and plans to attend influential conferences, Novelogics is poised to make a significant impact in the field of oncology